Developments of antifungal agents have declined as compared to other antibiotics that have displayed a potent development with time. There is an urgent need for both prophylactic and therapeutic treatments worldwide to control the severity of infections caused by Candida. Anticandidal Therapeutics: Discovery and Development provides the readers with a compiled knowledge of the fungal human infection Candida and the development of anticandidal drugs. Anticandidal Therapeutics helps researchers form the basis for the discovery and development of novel anticandidal therapies. In 14 chapters this book provides collective information on anticandidal agents and their discovery and development with respect to major drug transporter families, different stages of anticandidal agent development, recent trends and progress in antifungal translational research, clinical studies status of anticandidal therapeutic agents, and drug repurposing for development of novel anticandidal agents.
- Highlights the mechanistic actions of some therapeutic agents against Candida
- Focuses on anticandidal agents rather than general antifungal agents
- Discusses the stage of development of new antifungal drugs, the repositioning of drugs, and how this could help in treatment
1. History of infection
2. Brief introduction on infection
3. Fungal diseases and antifungal drugs
4. Multidrug transporters of fungal pathogen Candida
5. Essential anticandidal targets
6. Stages of anticandidal agent development
7. Recent trends and progress in antifungal translational research
8. Clinical status of anticandidal therapeutic agents
9. Drug repurposing for development of effective anticandidals
10. Commercial aspects of drug development
11. Challenges and future prospects
Dr. Awanish Kumar is currently an Associate Professor in the Department of Biotechnology at the National Institute of Technology, Raipur (CG), India. He has more than 13 years of research experience. He received his PhD in molecular parasitology from the CSIR-Central Drug Research Institute, Lucknow, India, and Jawaharlal Nehru University, Delhi, India, and completed his postdoctoral studies at McGill University, Montreal, Canada. His research interests are infection biology, drug targeting, and drug discovery. He has served on various national and international organizations in different academic and research capacities. He has also served on many national committees and scientific advisory panels, as a member of many international professional research societies, and as a reviewer and editorial board member of reputed and refereed journals. He has authored or edited several monographs, books, and book chapters.
Dr. Anubhuti Jha works in the area of antifungal drug discovery. She has obtained PhD degree from Department of Biotechnology, National Institute of Technology, Raipur (CG), India. She has published more than 15 research paper in peer_x0002_reviewed journals and has authored several books/chapters.
Lisainfo e-raamatute kohta